Mirum Pharmaceuticals, Inc.
MIRM · XNASCIK 1759425fmd_17TSEZ8WKV3D2JXMRTMQQHRGB2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 33 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 19 | 77 | 186 | 337 | 521 |
| Research and development | 43 | 82 | 131 | 107 | 103 | 141 | 186 |
| Selling, general and administrative | – | – | 59 | 89 | 146 | 202 | 257 |
| Total operating expenses | 55 | 104 | 193 | 208 | 296 | 424 | 543 |
| Operating income | (55) | (104) | (173) | (131) | (109) | (88) | (22) |
| Interest expense | – | – | – | 16 | 15 | 14 | 14 |
| Interest and investment income | 2 | 2 | 0 | 4 | 14 | 14 | 13 |
| Other non-operating income (expense) | (0) | (0) | (1) | 0 | (3) | 1 | 2 |
| Income before taxes | (53) | (103) | (84) | (142) | (162) | (87) | (21) |
| Income tax expense | 0 | 0 | 0 | (6) | 1 | 1 | 2 |
| Net income from continuing operations | (53) | (103) | (84) | (136) | (163) | (88) | (23) |
| Net income | (53) | (103) | (84) | (136) | (163) | (88) | (23) |
| Net income to common shareholders | – | – | (84) | (136) | (163) | (88) | – |